PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.45%
Negative revenue growth while Medical - Pharmaceuticals median is 1.19%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-3.98%
Negative gross profit growth while Medical - Pharmaceuticals median is 1.10%. Seth Klarman would suspect poor product pricing or inefficient production.
-17.81%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-20.34%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-18.30%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-18.29%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-18.29%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.35%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 2.18%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
4.35%
5Y revenue/share growth near Medical - Pharmaceuticals median of 4.39%. Charlie Munger might see typical industry or economic growth patterns.
-22.63%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 5.15%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
84.25%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 33.83% over a decade. Joel Greenblatt might see a standout compounder of earnings.
84.25%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 15.55%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
3.41%
3Y net income/share CAGR of 3.41% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
37.80%
Equity/share CAGR of 37.80% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
37.80%
5Y equity/share CAGR of 37.80% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-6.14%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
11.89%
Inventory growth of 11.89% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
6.36%
Asset growth of 6.36% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.37%
BV/share growth of 5.37% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
307.59%
Debt growth of 307.59% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
2.63%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.